FeesSafety
Pluang+

Tokenized funds dominate Solana's $4.8B real-world asset market with $3.7B value.

Protocol Fundamentals
09 Nov 2026, 10:14 WIB
Tokenpost
View Source
Neutral
Tokenized funds dominate Solana's $4.8B real-world asset market with $3.7B value.

Tokenized funds represent the largest share of Solana's $4.8 billion real-world asset market, accounting for $3.7 billion. Tokenized stocks are valued at $1.1 billion, while commodities hold $31.9 million. This distribution highlights the prominence of funds over stocks and commodities on the Solana network. The figures reflect market value at an unspecified time, not trading volume.

Tokenized funds in Solana's real-world asset market are valued at $3.7 billion within a total $4.8 billion market. For readers following Pluang's cryptocurrency market, as of Nov 09, 2026 14:51 WIB, out of 50 major cryptocurrencies, 5 rose and 44 fell. Notable movers include SNX at Rp2.780 with a 1-day change of -6.59%, ETH at Rp37.883.855 down 6.36%, and XTZ at Rp4.404 down 5.55%.

More News

Oculis to host R&D Day showcasing late-stage pipeline for dry eye and neuro-ophthalmology treatments

Oculis to host R&D Day showcasing late-stage pipeline for dry eye and neuro-ophthalmology treatments

Oculis Holding AG announced an in-person and virtual R&D Day on December 8, 2026, to highlight key clinical developments in its late-stage pipeline, including Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmology and neurology. The...

Market News
Bullish
1 hour ago
DNO ASA's offer for Capricorn Energy plc lapses, ending the acquisition attempt.

DNO ASA's offer for Capricorn Energy plc lapses, ending the acquisition attempt.

DNO ASA announced that its offer to acquire Capricorn Energy plc has lapsed as of November 9, 2026. This means the acquisition attempt will not proceed, impacting DNO's expansion plans in the oil and gas sector. Investors should monitor DNO's next st...

Market News
Neutral
1 hour ago
Oculis announces R&D Day to showcase late-stage eye disease drug developments Licaminlimab and Privosegtor.

Oculis announces R&D Day to showcase late-stage eye disease drug developments Licaminlimab and Privosegtor.

Oculis Holding AG will hold a Research & Development Day on December 8, 2026, to present key clinical progress on its late-stage drug candidates Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmic conditions including optic neuritis...

Company Fundamentals
Bullish
1 hour ago
Fraudulent robocall losses in North America to drop 33% by 2031 due to advanced fraud prevention.

Fraudulent robocall losses in North America to drop 33% by 2031 due to advanced fraud prevention.

Juniper Research forecasts that losses from fraudulent robocalls in North America will decrease by 33%, from $18.4 billion in 2026 to $12.3 billion in 2031. This decline is attributed to telecom operators adopting advanced fraud prevention technologi...

Market News
Bullish
1 hour ago
HTX launches 20 tokenized US stocks for spot trading with zero maker fees until Feb 2027.

HTX launches 20 tokenized US stocks for spot trading with zero maker fees until Feb 2027.

HTX, a cryptocurrency exchange, has launched spot trading for 20 tokenized U.S. stocks and ETFs against USDT starting November 9, 2026. These tokenized stocks provide economic exposure to companies like Nvidia, Tesla, and Google but do not confer dir...

Market News
Bullish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App